University of Kansas School of Medicine Wichita, KS
Mohamed Omar, MD1, David Maundu, MBChB, MSc-HCM, MSc-ID2, Sandra Chehayeb, MD1, Joshua Musalia, MD3, Hayder Alamily, MD4, William J.. Salyers, MD, MPH5, Nathan Tofteland, MD1, W. Ransom. Kilgore, MD6 1University of Kansas School of Medicine, Wichita, KS; 2KU School of Medicine-Wichita, Wichita, KS; 3University of Cincinnati College of Medicine, Cincinnati, OH; 4University of Colorado Anschutz Medical Campus, Denver, CO; 5University of Kansas School of Medicine - Wichita, Wichita, KS; 6Ascension Saint Francis Hospital, Wichita, KS Introduction: Sarcopenia, characterized by the progressive loss of skeletal muscle mass and strength, is increasingly acknowledged in chronic inflammatory conditions like inflammatory bowel disease (IBD). Our objective was to assess the association between sarcopenia and inpatient outcomes among IBD patients utilizing data from a national database. Methods: We conducted a retrospective cohort study utilizing five years of data from the National Inpatient Sample (2017–2022). Our analysis focused on adult hospitalizations with a primary or secondary diagnosis of inflammatory bowel disease (Crohn’s disease and ulcerative colitis) that also included a diagnosis of sarcopenia. We identified cases using a comprehensive array of diagnostic codes. To evaluate the associations with inpatient mortality, infections, ICU stays (approximated through mechanical ventilation), major IBD-related surgeries, venous thromboembolism (VTE), length of stay (LOS), and total hospital charges, we employed multivariable logistic and linear regression models. The analysis was conducted using STATA 18. Results: From a weighted total of 1,591,464 IBD-related hospitalizations, 2.8% had co-diagnosed sarcopenia. Compared to non-sarcopenic patients, sarcopenic IBD patients had significantly higher odds of mortality [aOR 2.10 (95% CI 1.89–2.34)], infections [aOR 1.14 (95% CI 1.05–1.24)], ICU stay [aOR 1.24 (95% CI 1.12–1.38)]. They also had more extended hospital stays (mean difference +0.92 days, p< 0.001) and higher total charges (+$3,849, p=0.024). Sarcopenia reduced the odds of undergoing major IBD-related surgery in this cohort [aOR 0.71 (95% CI 0.64–0.79)] but had no significant difference in development of VTE [aOR 1.09 (95% CI 0.99-1.20)]. Sensitivity analysis using a strict sarcopenia definition yielded consistent but non-significant trends. Subgroup analysis showed that sarcopenic patients with obesity had similar mortality and infection outcomes compared to those without obesity. Discussion: Sarcopenia is independently linked to poorer inpatient outcomes and increased healthcare utilization in hospitalized patients with inflammatory bowel disease. The lower likelihood of requiring major IBD-related surgeries in this population may indicate underlying frailty and heightened surgical risk. It may be beneficial to implement routine screening and targeted interventions for sarcopenia, such as nutritional support and physical therapy, to enhance clinical outcomes within this group.
Disclosures: Mohamed Omar indicated no relevant financial relationships. David Maundu indicated no relevant financial relationships. Sandra Chehayeb indicated no relevant financial relationships. Joshua Musalia indicated no relevant financial relationships. Hayder Alamily indicated no relevant financial relationships. William Salyers indicated no relevant financial relationships. Nathan Tofteland indicated no relevant financial relationships. W. Kilgore: Vanda Pharmaceuticals – Grant/Research Support.
Mohamed Omar, MD1, David Maundu, MBChB, MSc-HCM, MSc-ID2, Sandra Chehayeb, MD1, Joshua Musalia, MD3, Hayder Alamily, MD4, William J.. Salyers, MD, MPH5, Nathan Tofteland, MD1, W. Ransom. Kilgore, MD6. P5310 - Impact of Sarcopenia on Inpatient Outcomes Among Patients Hospitalized With Inflammatory Bowel Disease: A Five-Year Nationwide Analysis, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
